Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;7(10):4943-4951.
doi: 10.1002/cam4.1750. Epub 2018 Sep 6.

Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study

Lydia G M van der Geest  1 , Casper H J van Eijck  2 , Bas Groot Koerkamp  2 , Valery E P P Lemmens  1   3 , Olivier R Busch  4 , Pauline A J Vissers  1 , Johanna W Wilmink  5 , Marc G Besselink  4 ; Dutch Pancreatic Cancer Group
Affiliations

Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study

Lydia G M van der Geest et al. Cancer Med. 2018 Oct.

Abstract

Background: Nonresected, nonmetastatic (NR-M0) pancreatic cancer involves both locally advanced pancreatic cancer and patients who did not undergo resection due to poor health status or patient preference. This study investigates nationwide trends of characteristics, treatment, and survival of patients with NR-M0 pancreatic cancer.

Methods: From the Netherlands Cancer Registry, all patients diagnosed with pancreatic cancer between 2006 and 2014 were selected. Chemotherapy and overall survival (OS) of NR-M0 patients were evaluated for 3-year time periods and 2 age groups using chi-square tests for trend and Cox proportional hazard regression analysis.

Results: Of 18 234 patients, 33% had NR-M0 pancreatic cancer, which decreased over time (in consecutive 3-year periods: 38%-33%-28%, P < 0.001). Of 5964 NR-M0 patients, 52% was over 75 years of age, 16% received chemotherapy, and median OS was 5.1 months. Chemotherapy use increased over time in younger patients (<75 years: from 23 to 36%, P-trend < 0.001, ≥75 years: 3% to 4%, P-trend = 0.053). In multivariable survival analysis, elderly age, low SES, nonconfirmed cancer, stage II-III disease, and earlier years of diagnosis were independently associated with a worse OS. Age of patients who received chemotherapy increased over time (median 62-66 years) and median OS was 10.4 months without significant differences between time periods (P = 0.177) or age groups (P = 0.207).

Conclusions: Overall survival of NR-M0 pancreatic cancer remains poor which is partly related to advanced age of many patients. Despite an increase, chemotherapy is infrequently used. Future research should investigate to what extent the more widespread use of chemotherapy could improve survival in relation to age-related morbidity.

Keywords: chemotherapy; nonresected; pancreatic adenocarcinoma; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of resected, nonresected nonmetastatic (NR‐M0), and metastatic (M1) pancreatic cancer, by periods within younger and elderly age categories (both P < 0.001)
See this image and copyright information in PMC

References

    1. Netherlands Cancer Registry (NCR) . Dutch Cancer Figures. http://www.cijfersoverkanker.nl/. Accessed April 01, 2018.
    1. Lepage C, Capocaccia R, Hackl M, et al. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999‐2007: results of EUROCARE‐5. Eur J Cancer. 2015;51(15):2169‐2178. - PubMed
    1. Bernards N, Haj Mohammad N, Creemers GJ, de Hingh IH, van Laarhoven HW, Lemmens VE. Ten weeks to live: a population‐based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Acta Oncol. 2015;54(3):403‐410. - PubMed
    1. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14(4):1320‐1326. - PubMed
    1. Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33(16):1770‐1778. - PubMed